Aktueller Stellenwert von Dronedaron in der Therapie des Vorhofflimmerns

Abstract

Atrial fibrillation (AF) is the most frequently encountered sustained cardiac arrhythmia. Effective pharmacological treatment of AF remains an unmet cardiovascular need. The class III antiarrhythmic drug dronedarone has been developed to provide rhythm and rate control in AF patients with fewer side effects compared to amiodarone. Dronedarone significantly reduced the incidence of hospitalization due to cardiovascular events or death in patients with paroxysmal and persistent atrial fibrillation but was associated with increased rates of heart failure, stroke and death from cardiovascular causes in patients with permanent atrial fibrillation. Clinical trial data are critically reviewed and recommendations for routine practice are discussed.

• Literatur

• 1 Camm AJ. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
• 2 Schmidt C, Kisselbach J, Schweizer PA et al. The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. Vasc Health Risk Manag 2011; 7: 193-202
• 3 Thomas D, Scholz EP, Schweizer PA et al. Initial experience with robotic navigation for catheter ablation of paroxysmal and persistent atrial fibrillation. J Electrocardiol 2011; DOI: 10.1016/j.jelectrocard.2011.05.005.
• 4 Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 2005; 23: 217-230
• 5 Schweizer PA, Becker R, Katus HA et al. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther 2011; 5: 27-39
• 6 Thomas D, Kathofer S, Zhang W et al. Acute effects of dronedarone on both components of the cardiac delayed rectifier K⁺ current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol 2003; 140: 996-1002
• 7 Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678
• 8 Page RL, Connolly SJ, Crijns HJ et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol 2011; 107: 1019-1022
• 9 Connolly SJ, Camm AJ, Halperin JL et al. Dronedarone in high-risk permanent atrial fibrillation. New Engl J Med 2011; 365: 2268-2276
• 10 Freemantle N, Lafuente-Lafuente C, Mitchell S et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011; 13: 329-345